Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 186,372 Merit Medical Systems, Inc. $MMSI

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the second quarter, Holdings Channel reports. The institutional investor acquired 186,372 shares of the medical instruments supplier’s stock, valued at approximately $12,923,000.

Other institutional investors have also recently modified their holdings of the company. State Street Corp lifted its holdings in shares of Merit Medical Systems by 1.5% during the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after purchasing an additional 32,459 shares during the period. Conestoga Capital Advisors LLC boosted its position in Merit Medical Systems by 3.9% in the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock valued at $149,407,000 after buying an additional 81,030 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after buying an additional 234,682 shares during the period. Wellington Management Group LLP increased its holdings in Merit Medical Systems by 7.0% in the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock worth $116,963,000 after buying an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Merit Medical Systems by 1.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock worth $85,287,000 after buying an additional 12,285 shares during the period. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Merit Medical Systems Stock Up 0.9%

Merit Medical Systems stock opened at $91.09 on Wednesday. The business’s 50-day moving average price is $78.35 and its 200 day moving average price is $72.66. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The firm has a market cap of $5.44 billion, a price-to-earnings ratio of 37.64, a price-to-earnings-growth ratio of 2.25 and a beta of 0.49. Merit Medical Systems, Inc. has a 52 week low of $59.74 and a 52 week high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The company had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. During the same period in the previous year, the company posted $1.01 earnings per share. Merit Medical Systems’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, sell-side analysts anticipate that Merit Medical Systems, Inc. will post 3.84 earnings per share for the current year.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. Estimates were also raised for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, suggesting improving expectations for Merit Medical’s earnings trajectory.
• Positive Sentiment: Growth initiatives are strengthening the investment case: New product launches, acquisitions and a broader portfolio of therapeutic medical products are supporting stronger growth and improving the company’s business mix. Recent quarterly results also showed revenue growth and an EPS beat, while the company raised its 2026 outlook. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares both on August 10 and August 25, with a zero-day days-to-cover ratio. The reported “increase” is mathematically invalid, so the data does not indicate either meaningful short covering or rising bearish positioning.
• Negative Sentiment: Valuation and risk remain concerns: MMSI’s recent rally has left the stock trading at a premium valuation, increasing the need for continued earnings delivery. Analysts also cited tariff exposure and execution risks related to launches and acquisitions as potential headwinds. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Wall Street Analyst Weigh In

MMSI has been the subject of several research reports. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Raymond James Financial reissued an “outperform” rating and set a $100.00 target price on shares of Merit Medical Systems in a report on Friday, July 31st. Piper Sandler raised their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Bank of America boosted their target price on shares of Merit Medical Systems from $92.00 to $97.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.00.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.